New rapid tests aim to speed up ebola and lassa fever diagnosis
NCT ID NCT07681752
First seen Jul 02, 2026 · Last updated Jul 02, 2026
Summary
This study evaluates two new diagnostic tests (FORTIFIEDx and DECIPHER) for detecting Ebola and Lassa viruses. Researchers will use stored blood and cheek swab samples from patients in Guinea to see how well these tests compare to the standard PCR method. The goal is to determine if these faster, simpler tests can accurately identify infections, which could help in future outbreaks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- FORTIFIEDx and DECIPHER bioassays (diagnostic tests using isothermal nucleic acid amplification)
- What this could lead to
- If accurate, these tests could enable faster, simpler diagnosis of Ebola and Lassa fever in remote areas, improving outbreak response.
- What could go wrong
- This is a retrospective study using stored samples, not a real-world test. The new tests may not perform as well in field conditions or detect all cases.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EBOLA HEMORRHAGIC FEVER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.